Who owns Allogene Therapeutics, Inc. (ALLO)? Elite investor 13F holders
2 tracked elite investors reported holding Allogene Therapeutics, Inc as of 2026-06-30, including D.E. Shaw, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | ALLOGENE THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 9798329.00 USD | 4710735.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | ALLOGENE THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 7975369.00 USD | 3834312.000000 | Shares | add | Original filing |
| Tudor Investment | ALLOGENE THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.